Article info

Download PDFPDF
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

Authors

  1. Correspondence to Dr Seoyoung C Kim, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA 02120, USA; sykim{at}bwh.harvard.edu
View Full Text

Citation

Pawar A, Desai RJ, Solomon DH, et al
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

Publication history

  • Received August 30, 2018
  • Revised December 10, 2018
  • Accepted December 29, 2018
  • First published January 24, 2019.
Online issue publication 
March 12, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.